INM Form 3 shows director’s 3,500 stock options at $2.1

Rhea-AI Filing Summary

InMed Pharmaceuticals (INM) reported an initial statement of beneficial ownership by a director. The filing lists an employee stock option to purchase 3,500 common shares at an exercise price of $2.1, with an expiration date of 10/16/2030.

The event date is 10/14/2025. According to the vesting terms, the options were granted on 10/17/2025 and will vest monthly, in arrears: 98 options on the 17th of each month for 35 months, and 70 options on 10/17/2025. Ownership is reported as Direct.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bathery John Steven

Role Director

Type	Security	Shares	Price	Value
holding	Employee Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 3,500 shares (Direct)

Footnotes (1)

1. F1. The options were granted on Oct 17, 2025 and will vest monthly, in arrears, as follows: (i) 98 stock options will vest on the 17th day of each month for 35 months, and (ii) 70 stock options will vest on Oct 17, 2025 (the three year anniversary of Grant date).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 10/23/2025 - 07:31 PM Learn about SEC filing dates

FAQ

What did InMed (INM) disclose in this Form 3?

A director reported an employee stock option for 3,500 common shares at an exercise price of $2.1, expiring on 10/16/2030.

What is the vesting schedule for the INM options?

The options were granted on 10/17/2025 and vest monthly: 98 options on the 17th of each month for 35 months, plus 70 options on 10/17/2025.

What role does the reporting person have at INM?

The individual is a Director of InMed Pharmaceuticals Inc.

What is the date of the event requiring this statement?

The event date is 10/14/2025.

How are the options held according to the filing?

The options are held with Direct ownership.

What class of securities underlies the derivative?

The derivative is an employee stock option on common shares.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bathery John Steven

(Last) (First) (Middle)

C/O INMED PHARMACEUTICALS INC

1445-885 WEST GEORGIA ST.

(Street)

VANCOUVER A1 V6C3E8

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/14/2025

3. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ INM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	10/16/2030	Common shares	3,500	$2.1	D

Explanation of Responses:

1. The options were granted on Oct 17, 2025 and will vest monthly, in arrears, as follows: (i) 98 stock options will vest on the 17th day of each month for 35 months, and (ii) 70 stock options will vest on Oct 17, 2025 (the three year anniversary of Grant date).

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Eric Adams, attorney-in-fact for Mr. John Bathery	10/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.